In this report, we present an update of the 2020 primary systematic review, to take into account more recent evidence on the efficacy, effectiveness and safety of newer and/or enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.
This report provides an integrated analysis of relationships between antimicrobial consumption in humans and food- producing animals and the occurrence of antimicrobial resistance in bacteria from humans and food- producing animals, respectively.
Seasonal influenza is a vaccine-preventable disease and annual influenza vaccination is the most effective way to prevent influenza. ECDC continues to emphasise that all Europeans who are recommended to have the influenza vaccine should get vaccinated.
This document presents the core protocol for ECDC studies of CVE and IVE against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection, respectively, at primary care level.